14-loflin-pharmacologic methods of contraception...hormonal contraception can worsen or cause...
TRANSCRIPT
4/4/2019
1
� Explain the physiology of the normal menstrual cycle and the role contraceptives play in preventing pregnancy
� Discuss methods of contraception and their pharmacologic properties
� Identify patient populations that require special considerations
1
2
4/4/2019
2
� Median length is 28 days, but can last from 21 to 40 days
� Begins with menarche, usually around 12 years of age, and ends with menopause, usually around 50 years of age
� Comprised of three phases: follicular phase, ovulation, and luteal phase
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
Menses begins
Follicle Stimulating Hormone
(FSH) levels rise
One dominant follicle
secretes estradiol,
progesterone, and androgen
Menses is stopped
The endometrial lining of the
uterus is thickened and thin, watery
cervical mucus is
produced
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
3
4
4/4/2019
3
Mid-menstrual cycle the
anterior pituitary releases a surge
of luteinizing hormone (LH)
and the follicle releases a surge
of estrogen
This triggers follicular rupture and the release
of an oocyte
The oocyte then travels to the
fallopian tube to be fertilized and
the uterus for implantation
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
Non-dominant follicles form the corpus
luteum, which synthesizes estrogen,
progesterone, and androgen
Corpus luteum degenerates
and progesterone
declines
Progesterone
maintains the
endometrial
lining for the
embryo
Endometrial shedding
occurs and menstrual
cycle starts over
Human
chorionic
gonadotropin
(HCG)
stimulates
progesterone
and estrogen
production
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
5
6
4/4/2019
4
� Ethinyl estradiol
� Stabilizes endometrial lining and provides cycle control
� Contraceptive mechanism
› Suppress FSH release, which may prevent LH surge and subsequently prevent ovulation
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
� First generation: norethindrone, norethindrone acetate
� Second generation: levonorgestrel and norgestrel
� Third generation: norgestimate� Fourth generation: drospirenone� Provide most of the contraceptive effect� Contraceptive mechanism› Thicken cervical mucus to prevent sperm
penetration and slow motility
› Enhance endometrial atrophy
› Block LH surge and subsequently prevent ovulation
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014PL Detail-Document, Hormonal Contraception. Pharmacist’s Letter/Prescriber’s Letter. March 2013.
7
8
4/4/2019
5
� Low-Dose vs. High-Dose
› Refers to the dose of ethinyl estradiol (EE)
› Doses range from 10 mcg/day to 35
mcg/day
� “-phasic” (ex: mono-, bi-, tri-, four-)
› Refers to the number of different doses of
estrogen, progesterone, or both
› For example: triphasic Ortho Tri-Cyclen®
contains EE 35 mcg and norgestimate 0.18
mg x 7d, 0.215 mg x 7d, and 0.25 mg x 7d
� Extended-Cycle› Most provide active pills for 84 days
› Followed by either 7 days with low-dose estrogen or 7 days pill-free
� Continuous-Cycle› Continuous active pills
› Amethyst® is the only product available in the U.S.
� Can mimic these regimens with monophasic oral contraceptives
Clinical Resource, Comparison of Oral Contraceptives and Non-Oral Alternatives. Pharmacist’s Letter/Prescriber’s Letter. February 2018.
9
10
4/4/2019
6
� A good starting place for most women is a product with 20 mcg EE and levonorgestrel/norethindrone
� Back-up contraception is needed for 7 days after initiation
� Consider coexisting medical conditions and risk factors when selecting a product
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014
Adverse Effect Likely Cause Response
Nausea, breast tenderness,
increased blood pressure,
melasma, headache
Too much estrogen Decrease estrogen content
Early or mid-cycle
breakthrough bleeding,
increased spotting,
hypomenorrhea
Too little estrogenIncrease estrogen content,
switch progestins
Breast tenderness, headache,
fatigue, changes in moodToo much progestin Decrease progestin content
Late breakthrough bleeding Too little progestin Increase progestin content
Increased appetite, weight
gain, acne, oily skin, hirsutism,
increased LDL, decreased HDL
Too much androgenSwitch to a third or fourth
generation progestin
Local irritationTransdermal patch or vaginal
ring useSwitch to an oral dosage form
PL Detail-Document, Hormonal Contraception. Pharmacist’s Letter/Prescriber’s Letter. March 2013.
11
12
4/4/2019
7
� Late dose = < 24 hours past intended administration
� Missed dose = ≥ 24 hours past intended administration
� Could increase adherence with use of the patch or vaginal ring
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66
� 0.35 mg norethindrone daily
� Less effective than CHCs
� More irregular and unpredictable bleeding
� Therapy of choice for patients immediately postpartum, breastfeeding, or postabortion
Clinical Resource, Comparison of Oral Contraceptives and Non-Oral Alternatives. Pharmacist’s Letter/Prescriber’s Letter. February 2018.
Shrader SP, Ragucci KR., Pharmacotherapy: A Pathophysiologic Approach, 9e. 2014.
13
14
4/4/2019
8
� Must be taken at approximately the same time everyday to maintain contraceptive efficacy
� Missed dose = > 3 hours past intended administration
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66
� Intramuscular or subcutaneous dosage forms
� Dose is repeated every 3 months (13 weeks)
› Can extend up to 15 weeks without backup
contraception use
� Can expect spotting and irregular periods for ~6 months. Most women develop amenorrhea
� Has increased incidence of weight gain (~3.7 kg over 2 years)
Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2019; Feb 22, 2019.
15
16
4/4/2019
9
� Subdermal implant
� Intrauterine devices (IUDs)
� Incidence of use is increasing
› From 2002 to 2012, IUD use in the U.S.
increased from 2% to 10% of all
contraception
� Little or nothing to remember to maintain efficacy
Madden T. Intrauterine contraception: Background and device types. In: UpToDate, Schreiber CA (Ed), UpToDate, Eckler K. (Accessed on March 1, 2019.)
� Nexplanon® (etonogestrel) 68 mg
� Releases ~65 mcg daily x 1 month, ~40 mcg daily x 1 year, ~35 mcg daily x 1 year, and then ~30 mcg daily x 1 year
� Can be left inserted for 3 years
� Most common adverse effect is irregular bleeding. Some women may develop amenorrhea
Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2019; Feb 22, 2019.
17
18
4/4/2019
10
� Mean levonorgestrel released is ~6 to ~15 mcg/day.
� Products provide either 3 or 5-year treatment lengths
� Require a follow-up 4-6 weeks after insertion to confirm placement
� Can expect increased bleeding or spotting for 3-6 months after placement. Some women develop amenorrhea.
Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2019; Feb 22, 2019.
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66.
� Non-hormonal
� 10-year treatment length
� Works by inhibiting sperm transport and egg fertilization
� Most common adverse effect is heavier, longer periods with spotting in between for 2-3 months (heavier bleeding than hormonal contraceptives)
� Contraindicated in Wilson’s Disease
Package insert. Paragard (intrauterine copper contraceptive). Trumball, CT: Copper Surgical, 2018.
19
20
4/4/2019
11
Regimen Formulation
Timing of Use After
Unprotected Sexual
Intercourse
Mechanism of Action
FDA Labeled for EC Use
Selective progesterone
receptor modulator
1 tablet of 30 mg ulipristal
acetateUp to 5 days
Inhibit or delay ovulation,
inhibits follicular rupture
Yes
Progestin only
1 tablet of 1.5 mg
levonorgestrel
2 tablets of 0.75 levonorgestrel
Up to 3 daysInhibit or delay
ovulation, delays follicular development
Yes
Progestin and estrogen pills
A variety can be used
Up to 5 days No
Copper IUD N/A Up to 5 daysAffects sperm motility and
functionNo
HCP, health-care professional; OTC, over-the-counterACOG., ACOG Practice Bulletin. 2015; 152: 1-11.
� Adverse Effects› Nausea
› Headache
› Irregular Bleeding
› Abdominal Cramping
� Any EC may be used by women with contraindications to traditional oral contraceptives
� Can begin using hormonal contraceptives 5 days after ulipristal use and immediately after levonorgestrel ± estrogen EC use
ACOG., ACOG Practice Bulletin. 2015; 152: 1-11.
21
22
4/4/2019
12
Contraceptive Adverse Effect
CHCs Venous thromboembolism (VTE)
CHCsStroke (in the setting of migraines with
aura)
Depot Medroxyprogesterone
Loss of bone mineral density
LNG - IUD Pelvic inflammatory disease
Other serious risks exist, mostly when used for indications other than contraception
� No contraindication based on age alone
� Age is an independent risk factor for cardiovascular disease (CVD) and thromboembolism
� Avoid estrogen-containing contraceptives
� If the patient smokes, estrogen is contraindicated
ACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
23
24
4/4/2019
13
� Share common risk factors with VTE
� Estrogen may increase the risk of hypercoagulability and stroke
� Estrogen may increase blood pressure
� Estrogen may increase triglycerides; progestins may increase LDL
� As the number of risk factors increases, the amount of consideration for hormonal contraceptive use should decrease
ACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
� Hormonal contraception can worsen or cause recurrence of disease
� All hormonal methods of contraception are considered an unacceptable health risk in patients with current cancer
� In those who have no evidence of disease for 5 years, the risks of hormonal contraception usually outweigh the benefits
� The Cu-IUD is the preferred methodACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66.
25
26
4/4/2019
14
� Anticonvulsant medications induce hepatic clearance of estrogen and progestin and decrease serum concentrations
› Carbamazepine, oxcarbazepine,
phenobarbital, phenytoin, primidone
� Depot injections and IUDs are preferred treatment for this reason
� If using CHCs consider drug dosages, half-lives, and interruptions when choosing a product
ACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
� Studies have shown obese women require twice as long to reach steady state with pill formulations
� Continuous-cycle or higher-dose estrogen products may be more effective
� Due to potential for reduced efficacy, the transdermal patch is not recommended in women >90 kg
� LNG-IUD and Cu-IUD efficacy not affected by body weight
ACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
Clinical Resource, Contraception for Women with Chronic Medical Conditions. Pharmacist’s Letter/Prescriber’s Letter. September 2016.
27
28
4/4/2019
15
� Efficacy may be impaired in women who have undergone surgery that may impair oral absorption (Roux-en-Y bypass)
� Preference non-oral formulations in these patients
� All forms of contraception are acceptable in women who have had restrictive-type procedures (banding, sleeves)
ACOG., ACOG Practice Bulletin. 2019; 133: e128-e150.
� Do not use CHCs for 3 weeks after delivery due to increased risk for VTE
› If additional VTE risk factors, avoid for 6
weeks after delivery
� Can receive progestin-only methods immediately
� CHCs can be started immediately after a first or second trimester abortion
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66.
29
30
4/4/2019
16
� LNG-IUD may be used immediately postpartum or following first or second trimester abortion.*
� Cu-IUD can either be placed immediately postpartum or in the second postpartum month*
*assuming normal uterus position after delivery
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66.
Package insert. Paragard (intrauterine copper contraceptive). Trumball, CT: Copper Surgical, 2018.
� Do not use CHCs for 4 weeks after delivery due to increased VTE risk and decreased breastmilk production
� If additional VTE risk factors, avoid for 6 weeks after delivery
� Can receive progestin-only methods immediately
� Lactation has been associated with an increased risk of IUD perforation
Curtis KM, et al. MMWR Recomm Rep. 2016; 65: 1-66.
Lexicomp Online, Lexi-Drugs, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2019; Feb 22, 2019.
31
32
4/4/2019
17
� Has been difficult to accomplish while maintaining libido
� Nestorone®/Testosterone transdermal gel
� Applied once daily to the shoulders and upper arms
� A phase II study is currently in progress
Popcouncil. 2018. https://www.popcouncil.org/news/20662.
� U.S. Selected Practice Recommendations for Contraceptive Use, 2016
› https://www.cdc.gov/mmwr/volumes/65/rr/
pdfs/rr6504.pdf
� The American College of Obstetricians and Gynecologists
› https://www.acog.org/Clinical-Guidance-
and-Publications/Search-Clinical-Guidance
33
34
4/4/2019
18
35